RGS16 and neoplasm: To accelerate the discovery of effective drugs that inhibit PDA in vivo, we developed Rgs16::GFP as a sensitive reporter of PanIN and PDA initiation, progression and tumor size by 4 weeks of age (P29) in KIC mice.